PAVmed Inc. (NASDAQ: PAVM) Reports Q2 2026 Financial Results and Operational Progress

• PAVmed Inc. (NASDAQ: PAVM) reported a GAAP diluted loss per share of $0.87 and a non-GAAP adjusted loss per share of $0.27, with the latter better than the analyst estimate of a $0.47 loss.
• PAVmed generated $33,000 in revenue, below the consensus estimate of approximately $49,000. Separately, Lucid Diagnostics reported $1.5 million in revenue and processed 2,770 EsoGuard® tests.
• Veris Health continued developing its implantable physiological monitor toward a planned FDA 510(k) submission in early 2027.

PAVmed Inc. (NASDAQ: PAVM) is a diversified medical technology company operating across the medical-device, diagnostics, and digital-health sectors. Its businesses include Veris Health, which develops remote cancer-care monitoring technology, and medical-device companies PortIO and Octeris. PAVmed also holds a significant investment in Lucid Diagnostics, which focuses on detecting esophageal precancer.

On August 14, 2026, PAVmed reported its second-quarter financial results. The company recorded a GAAP net loss attributable to common stockholders of approximately $5.5 million, or $0.87 per diluted share. Its non-GAAP adjusted net loss was approximately $1.7 million, or $0.27 per share, compared with an analyst estimate of a $0.47 loss per share.

PAVmed generated $33,000 in revenue during the quarter, up from $6,000 a year earlier but below the consensus estimate of approximately $49,000. Lucid Diagnostics’ revenue should be reported separately because PAVmed accounts for its investment in Lucid under the equity method rather than consolidating Lucid’s revenue into its own results.

Separately, Lucid Diagnostics reported $1.5 million in EsoGuard revenue and processed 2,770 EsoGuard tests during the quarter. Lucid also secured its first laboratory benefit manager coverage policy for EsoGuard, which recognizes the test as medically necessary for qualifying patients and has been adopted by multiple client health plans.

Veris Health continued developing its implantable physiological monitor, with an FDA 510(k) submission planned for early 2027. The company also expanded patient onboarding through its commercial engagement with The Ohio State University Comprehensive Cancer Center—The James.

PAVmed remains unprofitable, so a negative P/E ratio is not meaningful for valuation purposes. The company ended the quarter with $3.8 million in cash and cash equivalents, compared with $6.5 million at the end of the previous quarter and $1.5 million at the end of 2025.